This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Donahue KE et al. (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148: 124–134
Boers M et al. (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350: 309–318
Landewé RB et al. (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46: 347–356
Grigor C et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364: 263–269
Grigor C et al. (2006) 5-year follow-up of the trial of Tight Control for Rheumatoid Arthritis (TICORA) study. Arthritis Rheum 54: S310
Verstappen SM et al. (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443–1449
Goekoop-Ruiterman YP et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381–3390
van der Bijl AE et al. (2007) Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56: 2129–2134
Goekoop-Ruiterman YP et al. (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146: 406–415
van Dongen H et al. (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56: 1424–1432
Gonzalez A et al. (2007) The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 56: 3583–3587
Author information
Authors and Affiliations
Ethics declarations
Competing interests
MH Weisman has received research grants from the following companies: Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Human Genome Sciences, UCB, Wyeth and XDx Expression Diagnostics. MH Weisman is a consultant/advisor/member of Data-Safety Monitoring Board for the following companies: Abbott, Amgen, Array, Biogen, Centocor, Elan, Genentech, Human Genome Sciences, Merck, TAP, UCB and Wyeth.
Rights and permissions
About this article
Cite this article
Weisman, M. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?. Nat Rev Rheumatol 4, 298–299 (2008). https://doi.org/10.1038/ncprheum0806
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0806
This article is cited by
-
Vaccination with endosomal unknown epitopes produces therapeutic response in rheumatoid arthritis patients and modulates adjuvant arthritis of rats
Journal of Translational Medicine (2016)